The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma

Given the significant activity and tolerability of bendamustine, rituximab, and bortezomib in patients with relapsed indolent and mantle cell non-Hodgkin lymphoma, and laboratory studies suggesting synergistic activity, we conducted a multicenter phase 2 study of the bendamustine/bortezomib/rituxima...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Friedberg, Jonathan W., Vose, Julie M., Kelly, Jennifer L., Young, Faith, Bernstein, Steven H., Peterson, Derick, Rich, Lynn, Blumel, Susan, Proia, Nicole K., Liesveld, Jane, Fisher, Richard I., Armitage, James O., Grant, Steven, Leonard, John P.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2011
Aiheet:
Clinical Trials and Observations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3062293/
https://ncbi.nlm.nih.gov/pubmed/21239695
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-11-314708
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia